Cryo-Cell International Inc (CCEL) stock
CCELNYSEServices-Misc Health & Allied Services, NECFiscal year ends November 30
$4.85−0.55 (-10.19%)
Close on Nov 13, 2026Market cap $39.10MP/E –Yield –
Cryo-Cell International EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cryo-Cell International's EPS for the twelve months ending Aug 31, 2026 was -$0.24. For fiscal 2025 it was -$0.30, down 700.0% from the year before. The highest annual figure on record is $0.83 in fiscal 2015.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -$0.30 | -700.0% |
| FY2024 | Nov 30, 2024 | $0.05 | – |
| FY2023 | Nov 30, 2023 | -$1.14 | -445.5% |
| FY2022 | Nov 30, 2022 | $0.33 | +32.0% |
| FY2021 | Nov 30, 2021 | $0.25 | -44.4% |
| FY2020 | Nov 30, 2020 | $0.45 | +66.7% |
| FY2019 | Nov 30, 2019 | $0.27 | – |
| FY2018 | Nov 30, 2018 | -$0.11 | -136.7% |
| FY2017 | Nov 30, 2017 | $0.30 | – |
| FY2016 | Nov 30, 2016 | -$0.16 | -119.3% |
| FY2015 | Nov 30, 2015 | $0.83 | +1560.0% |
| FY2014 | Nov 30, 2014 | $0.05 | – |
| FY2013 | Nov 30, 2013 | $0.00 | – |
| FY2012 | Nov 30, 2012 | -$0.56 | – |
| FY2011 | Nov 30, 2011 | -$0.18 | -162.1% |
| FY2010 | Nov 30, 2010 | $0.29 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $0.16 | +77.8% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $0.07 | +75.0% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $0.01 | -66.7% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$0.48 | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $0.09 | -30.8% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $0.04 | -50.0% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $0.03 | -57.1% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$0.23 | – |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $0.13 | +62.5% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $0.08 | +166.7% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $0.07 | -22.2% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -$1.36 | -1460.0% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $0.08 | +33.3% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $0.03 | -57.1% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $0.09 | -10.0% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $0.10 | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $0.06 | -40.0% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $0.07 | -50.0% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $0.10 | +25.0% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$0.07 | -146.7% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $0.10 | 0.0% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $0.14 | +16.7% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $0.08 | 0.0% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $0.15 | +50.0% |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $0.10 | -23.1% |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $0.12 | +1100.0% |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $0.08 | +166.7% |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $0.10 | -9.1% |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | $0.13 | +333.3% |
| Q2 FY2019CQ2 2019 | May 31, 2019 | $0.01 | -85.7% |
| Q1 FY2019CQ1 2019 | Feb 28, 2019 | $0.03 | – |
| Q4 FY2018CQ4 2018 | Nov 30, 2018 | $0.11 | +22.2% |
| Q3 FY2018CQ3 2018 | Aug 31, 2018 | $0.03 | -62.5% |
| Q2 FY2018CQ2 2018 | May 31, 2018 | $0.07 | +16.7% |
| Q1 FY2018CQ1 2018 | Feb 28, 2018 | -$0.36 | -614.3% |
| Q4 FY2017CQ4 2017 | Nov 30, 2017 | $0.09 | -25.0% |
| Q3 FY2017CQ3 2017 | Aug 31, 2017 | $0.08 | – |
| Q2 FY2017CQ2 2017 | May 31, 2017 | $0.06 | – |
| Q1 FY2017CQ1 2017 | Feb 28, 2017 | $0.07 | – |
| Q4 FY2016CQ4 2016 | Nov 30, 2016 | $0.12 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?